The novel oral anticoagulants: an update for the interventional radiologist.
OBJECTIVE
Thromboembolic disorders are leading causes of morbidity and mortality, with treatment and prophylaxis a priority. There has been a heavy dependency upon warfarin and heparin for anticoagulation for 60 years. This is likely to change with the emergence of novel oral anticoagulants.


CONCLUSIONS
Interventional radiologists are increasingly encountering these medications, and a thorough knowledge of them is essential for appropriate periprocedural management. This article will review these novel agents, their uses, and their pharmacologic profiles and will propose guidelines for periprocedural management.
Mater Misericordiae University Hospital, Dublin, Ireland. crockettmt@gmail.com
Matthew T
MT
Crockett
Michael R
MR
Moynagh
Eoin C
EC
Kavanagh
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D000069604:Dabigatran; D065427:Factor Xa Inhibitors; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use; D015641:Radiography, Interventional / Q000009:adverse effects*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000925:Anticoagulants; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran